Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: a randomized-controlled trial.

Effets du renversement du bloc neuromusculaire à l’aide de sugammadex vs de la néostigmine sur l’évolution respiratoire postopératoire après une chirurgie abdominale majeure: une étude randomisée contrôlée.

Journal

Canadian journal of anaesthesia = Journal canadien d'anesthesie
ISSN: 1496-8975
Titre abrégé: Can J Anaesth
Pays: United States
ID NLM: 8701709

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 11 09 2018
accepted: 22 04 2019
revised: 11 04 2019
pubmed: 6 6 2019
medline: 23 10 2020
entrez: 6 6 2019
Statut: ppublish

Résumé

Postoperative pulmonary complications may be better reduced by reversal of neuromuscular block with sugammadex than by reversal with neostigmine because the incidence of residual block after sugammadex application is lower and diaphragm function is less impaired than after neostigmine administration. The aim of the study was to compare the effect of reversal of neuromuscular block with sugammadex or neostigmine on lung function after major abdominal surgery. One hundred and thirty adults scheduled for major abdominal surgery under combined general and epidural anesthesia were randomly allocated to receive 40 µg of neostigmine or 4 mg·kg One hundred twenty-six patients were included in the main analysis. In the neostigmine group (n = 64), mean (95% confidence interval [95% CI]) reduction in FVC after one hour was 0.5 (0.4 to 0.6) L. In the sugammadex group (n = 62), the mean (95% CI) reduction in FVC during the first hour was 0.5 (95% CI, 0.3 to 0.6) L. Thirty-nine percent of patients in the neostigmine group and 29% in the sugammadex group had visible atelectasis. Median [interquartile range (IQR)] atelectasis area was 9.7 [4.7-13.1] cm We found no differences in pulmonary function in patients reversed with sugammadex or neostigmine in a high-risk population. EudraCT 2014-005156-26; registered 27 May, 2015.

Identifiants

pubmed: 31165457
doi: 10.1007/s12630-019-01419-3
pii: 10.1007/s12630-019-01419-3
doi:

Substances chimiques

Sugammadex 361LPM2T56
Neostigmine 3982TWQ96G

Types de publication

Comparative Study Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1328-1337

Subventions

Organisme : Merck
ID : ID# 51875

Auteurs

Enrique Alday (E)

Hospital Universitario La Princesa, C/Diego de León 62, 28006, Madrid, Spain. kikealday@hotmail.com.

Manolo Muñoz (M)

Hospital Universitario La Princesa, C/Diego de León 62, 28006, Madrid, Spain.

Antonio Planas (A)

Hospital Universitario La Princesa, C/Diego de León 62, 28006, Madrid, Spain.

Esperanza Mata (E)

Hospital Universitario La Princesa, C/Diego de León 62, 28006, Madrid, Spain.

Carlos Alvarez (C)

Hospital Universitario La Princesa, C/Diego de León 62, 28006, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH